Antiphospholipid antibodies and the endothelium

Rheum Dis Clin North Am. 2001 Aug;27(3):587-602. doi: 10.1016/s0889-857x(05)70222-2.

Abstract

The interaction between aPL (particularly anti-beta 2GPI antibodies) and endothelium does represent a potential pathogenetic mechanism for the thrombotic manifestations of the syndrome. The autoantibody-mediated EC activation probably plays a role in sustaining the appearance of a proadhesive, proinflammatory, and procoagulant phenotype. The heterogeneity of the APS clinical manifestations is likely linked to the varied effects that aPL can induce on ECs and to the different functions that ECs display depending on the anatomic localization.

Publication types

  • Review

MeSH terms

  • Antibodies, Antiphospholipid / immunology*
  • Blood Coagulation / immunology
  • Blood Coagulation / physiology
  • Blood Platelets
  • Cell Membrane
  • Endothelium / cytology
  • Endothelium / immunology*
  • Endothelium / pathology
  • Hemostasis
  • Humans
  • Phenotype
  • Platelet Glycoprotein GPIb-IX Complex / biosynthesis
  • Platelet Glycoprotein GPIb-IX Complex / immunology
  • Platelet Glycoprotein GPIb-IX Complex / pharmacology

Substances

  • Antibodies, Antiphospholipid
  • Platelet Glycoprotein GPIb-IX Complex